Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 19, 2008HaematologicaOpen Access

The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMeletios Α. DimopoulosEKEfstathios KastritisSDS. Delimpassi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dimopoulos et al. (2008) studied this question.

synapsesocial.com/papers/6a9dab44843eea9644fcffe8https://doi.org/10.3324/haematol.12846
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia2006 · 96 citations
  2. 2Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges2007 · 11 citations
  3. 3Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide2007 · 279 citations
  4. 4Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia2008 · 216 citations
  5. 5Treatment of Childhood Acute Nonlymphocytic Leukemia with High-Dose Cytosine Arabinoside, 6-Thioguanine, and Doxorubicin without Maintenance Therapy: Pilot Study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG)1988 · 13 citations